Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Immunotherapy and Chemotherapy in High-Risk Esophageal/EGJ Cancer
NCT04688801Recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Randomised, open-label trial in esophageal cancer and gastroesophageal junction cancer, sponsored by Second Hospital of Shandong University. Primary endpoints: Disease-Free Survival at 5 years and Overall Survival at 5 years. Started Jul 2020; status: recruiting.
02
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04688801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688801.